Patents by Inventor Stefan Kappe

Stefan Kappe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Live genetically attenuated malaria vaccine
    Publication number: 20070009556
    Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.
    Type: Application
    Filed: August 30, 2006
    Publication date: January 11, 2007
    Applicants: Seattle Biomedical Research Institute, Ruprecht-Karls-Universitat Heidelberg
    Inventors: Stefan Kappe, Kai-Uwe Matuschewski, Ann-Kristin Mueller
  • Live genetically engineered protozoan vaccine
    Publication number: 20060121060
    Abstract: The invention provides methods for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host. Representative protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida. The vertebrate host may be a mammal or a bird.
    Type: Application
    Filed: June 22, 2005
    Publication date: June 8, 2006
    Inventors: Stefan Kappe, Kai-Uwe Matuschewski
  • Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
    Publication number: 20050233435
    Abstract: The present invention relates to the treatment and prevention of malaria infection. In particular, the present invention provides novel noninfectious, whole organism vaccines for malaria, which vaccines comprise a Plasmodium axenic liver stage. The invention also provides methods to treat and prevent malaria by administering such Plasmodium axenic liver stage vaccines, as well as methods to generate Plasmodium axenic liver stages.
    Type: Application
    Filed: September 7, 2004
    Publication date: October 20, 2005
    Applicant: NYU Medical Center
    Inventors: Stefan Kappe, Victor Nussenzweig, Karine Kaiser, Nelly Camargo, Agam Singh
  • Live genetically attenuated malaria vaccine
    Publication number: 20050226896
    Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.
    Type: Application
    Filed: March 11, 2005
    Publication date: October 13, 2005
    Applicants: Seattle Biomedical Research Institute, Ruprecht-Karls-Universitat Heidelberg
    Inventors: Stefan Kappe, Kai-Uwe Matuschewski, Ann-Kristin Mueller
  • Plasmodium proteins useful for preparing vaccine compositions
    Patent number: 6120770
    Abstract: The present invention relates to DNA segments encoding MAEBL, an erythrocyte binding protein of a Plasmodium parasite, to substantially pure MAEBL proteins and to recombinantly or synthetically produced MAEBL molecules. The MAEBL proteins can be utilized as a vaccine for humans against malaria.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: September 19, 2000
    Assignee: University of Notre Dame du Lac
    Inventors: John H. Adams, Stefan Kappe, John P. Dalton